Revanesse Contour+ with Lidocaine

Revanesse

Aesthetic injectable

Cross-linked hyaluronic acid dermal filler for facial contouring

Classified and supplied as a medical device dermal filler based on cross Linked hyaluronic acid with lidocaine; not authorised as a medicinal product.
Manufactured by Prollenium Medical Technologies Inc. under medical device quality management systems and standards applicable to injectable HA fillers.
Marketed in many regions with CE marking as a hyaluronic acid dermal filler medical device, subject to local regulatory approvals.

Classified and supplied as a medical device dermal filler based on cross Linked hyaluronic acid with lidocaine; not authorised as a medicinal product.
Manufactured by Prollenium Medical Technologies Inc. under medical device quality management systems and standards applicable to injectable HA fillers.
Marketed in many regions with CE marking as a hyaluronic acid dermal filler medical device, subject to local regulatory approvals.
Use restricted to trained medical professionals in accordance with local regulations governing injectable aesthetic devices and dermal fillers.

Description

Revanesse Contour+ with Lidocaine is an ultra–high viscosity, cross-linked hyaluronic acid (HA) dermal filler developed by Prollenium Medical Technologies Inc. Specifically formulated for facial contouring and shaping, it is designed for large-volume treatments such as mid-face volumisation, chin and jaw augmentation, temple filling and nose bridge correction. The gel contains 25 mg/ml of high-viscosity cross-linked HA in phosphate-buffered saline, cross-linked with BDDE, and includes 0.3% (3 mg/ml) lidocaine to enhance patient comfort during injection. Supplied as a medical device for professional use only, each box contains two 1.2 ml prefilled glass syringes and two sterile 27G needles.

Bnefits

Ultra–high viscosity HA gel optimised for volumetric contouring and shaping of the face.
High HA concentration (25 mg/ml) designed to provide substantial and durable volume.
Contains 0.3% lidocaine to reduce pain and improve comfort during and immediately after injection.
Indicated for large-volume treatment areas such as temples, cheeks, chin, jawline and nose bridge.
Helps sculpt and contour facial features for a firm, lifted and more defined appearance.
Thixofix cross-linking technology aims to deliver a smooth injection, high shape retention and long-lasting results.
Implantation duration typically 12–18 months on average, depending on depth and treatment area.
Non-animal, cross-linked HA gel with established safety profile when used by trained medical professionals.

Indications

Restoration and addition of facial volume in large-volume areas by contouring and shaping.
Treatment of medium to deep facial rhytides and lipoatrophy by injection into the deep dermis to subcutaneous tissue.
Volumisation of the mid-face (cheeks and malar region).
Chin and jawline augmentation and contouring.
Nose bridge (dorsal) correction and contouring where appropriate and within the injector’s competence.
Treatment of deep folds, lines and wrinkles, including nasolabial folds and glabellar lines (brow area), when indicated.
Use in adult patients as a medical device dermal filler by appropriately trained medical professionals.